Celldex Therapeutics (CLDX) Expected to Announce Earnings on Wednesday

Celldex Therapeutics (NASDAQ:CLDX) is projected to announce its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($0.88) per share and revenue of $1.12 million for the quarter. Investors can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Friday, November 14, 2025 at 12:00 AM ET.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million for the quarter, compared to analyst estimates of $1.13 million. On average, analysts expect Celldex Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Celldex Therapeutics Stock Up 2.8%

CLDX stock opened at $26.73 on Monday. Celldex Therapeutics has a 12 month low of $14.40 and a 12 month high of $29.05. The firm has a market cap of $1.78 billion, a P/E ratio of -8.88 and a beta of 1.33. The company’s 50-day moving average price is $25.26 and its two-hundred day moving average price is $22.58.

Institutional Investors Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its stake in shares of Celldex Therapeutics by 27.6% in the 2nd quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares in the last quarter. Headlands Technologies LLC acquired a new stake in Celldex Therapeutics during the 2nd quarter worth approximately $125,000. Tower Research Capital LLC TRC boosted its position in Celldex Therapeutics by 289.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock worth $147,000 after buying an additional 5,387 shares during the period. Hsbc Holdings PLC acquired a new stake in Celldex Therapeutics during the 2nd quarter worth approximately $347,000. Finally, Jump Financial LLC boosted its position in Celldex Therapeutics by 53.3% during the 2nd quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 10,255 shares during the period.

Analysts Set New Price Targets

Several equities analysts have commented on CLDX shares. Wells Fargo & Company decreased their target price on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a report on Wednesday, August 20th. Barclays started coverage on shares of Celldex Therapeutics in a report on Monday, October 13th. They issued an “underweight” rating and a $25.00 target price on the stock. Mizuho started coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 target price on the stock. Citigroup decreased their target price on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Wednesday, August 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Celldex Therapeutics in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Celldex Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $44.20.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.